Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART.
OBJECTIVE
The objective of the study was to evaluate the immune response to measles vaccine of HIV-infected adults in comparison to HIV non-infected adults.


METHODS
We conducted a cross-sectional study to identify adults lacking measles antibodies. 26 HIV-infected patients and 22 controls found to be measles seronegative in the cross-sectional study, received the MMR vaccine. We prospectively followed patients and measured measles antibodies, and cellular proliferative responses against measles antigens. We registered all adverse events at baseline, 3 and 12 months after vaccination.


METHODS
We determined measles antibodies by ELISA and cellular proliferative response in PBMC's at baseline, and repeated measurements at 3 and 12 months after vaccination.


RESULTS
The humoral immune response to the vaccine between HIV-infected adults and the HIV-uninfected group was not statistically different at 3 months (81% vs. 86% respectively). One year after vaccination, a higher proportion of HIV-infected adults had lost measles antibodies in contrast to controls. The cellular response was not statistically different between the groups at baseline, 3 and 12 months after immunization despite the waning of antibodies at 12 months. No severe adverse events were observed. Most patients were receiving HAART and had a mean CD4+ cell count of 496 cells/mL.


CONCLUSIONS
The initial humoral immune response to measles vaccine was not different between HIV-infected adults and HIV-uninfected adults. However, HIV-infected adults have a rapid decline of measles antibodies despite their high CD4+ cell count and sustained cellular proliferative response.
Departamento de Infectologia, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Colonia Seccion XVI, Del. Tlalpan, Mexico, DF, CP 14000, Mexico. pbelaunz@googlemail.com
Pablo F
PF
Belaunzarán-Zamudio
Miguel L
ML
García-León
Rosa María
RM
Wong-Chew
Angelina
A
Villasís-Keever
Jennifer
J
Cuellar-Rodríguez
Juan L
JL
Mosqueda-Gómez
Teresa
T
Muñoz-Trejo
Kenia
K
Escobedo
José I
JI
Santos
Guillermo M
GM
Ruiz-Palacios
Juan G
JG
Sierra-Madero
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D023241:Antiretroviral Therapy, Highly Active; D049109:Cell Proliferation; D003430:Cross-Sectional Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D008297:Male; D008457:Measles / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D022542:Measles-Mumps-Rubella Vaccine / Q000276:immunology*; D008800:Mexico / Q000453:epidemiology; D011446:Prospective Studies; D016036:Seroepidemiologic Studies; D055815:Young Adult
D000914:Antibodies, Viral; D022542:Measles-Mumps-Rubella Vaccine